Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QEGR | ISIN: LT0000115768 | Ticker-Symbol: IGV0
Frankfurt
01.11.24
17:59 Uhr
19,700 Euro
+0,800
+4,23 %
Branche
Versorger
Aktienmarkt
OMX Baltic 10
1-Jahres-Chart
IGNITIS GRUPE AB Chart 1 Jahr
5-Tage-Chart
IGNITIS GRUPE AB 5-Tage-Chart
RealtimeGeldBriefZeit
18,98020,05013:04
GlobeNewswire (Europe)
115 Leser
Artikel bewerten:
(0)

Ignitis grupe: First six months 2024 interim report: strategy delivery with three Green Capacities projects reaching COD and 2024 guidance upgrade

AB "Ignitis grupe" (hereinafter - the Group) publishes its first six months 2024 interim report, which is attached to this notice, and announces that the Group's Adjusted EBITDA amounted to EUR 289.7 million (+14.3% YoY). The growth was driven by better results in Green Capacities and Networks segments and the Green Capacities segment remains the largest contributor with a 46.4% share of our total Adjusted EBITDA. Customers & Solutions segment electricity B2C activities remained to be loss-making (EUR -18.5 million).?

Our Investments amounted to EUR 422.3 million (+4.9% YoY) with 63.8% of them directed towards the Green Capacities segment, and 87.8% to Lithuania. The Investments into Green Capacities reached EUR 269.6 million (+15.2% YoY), with the majority directed towards new onshore wind farms in Lithuania.

The Group's leverage metrics remained strong, with FFO LTM/Net Debt ratio at a solid level of 32.0% (compared to 29.4% as of 31 December 2023). Also, S&P Global Ratings reaffirmed the Group's 'BBB+' (stable outlook) credit rating.

Business development

In 6M 2024, we increased our Green Capacities Portfolio to 7.7 GW (from 7.1 GW) and Installed Capacity to 1.4 GW (from 1.3 GW). Our Secured Capacity stood at 2.9 GW.

We reached a number of significant milestones in the expansion and development of our Green Capacities Portfolio, including the following:

- we, together with our partner CIP, won the second seabed site (Liivi 1) in the Estonian offshore wind tender and see the site as a natural extension of the Liivi 2 seabed site (secured in December 2023);

- Silesia WF I (50 MW) in Poland has reached COD;

- Vilnius CHP biomass unit has reached full COD (71 Mwe, 170 MWth);

- Taurage solar farm (22.1 MW) in Lithuania has reached COD;

- the first wind turbine has been erected in the largest wind farm under construction in the Baltics at Kelme WF I & II (300 MW) in Lithuania;

- we have secured land for the development of hybrid projects (314 MW), i.e., we are planning to develop wind farms near our Latvian solar projects;

- we have secured grid capacity for our first BESS projects (<260 MW) in Lithuania.

In Networks, we submitted the updated 10-year Investment Plan (2024-2033) to the regulator (NERC) for public consultation and coordination. The plan foresees a 40% increase in Investments to EUR 3.5 billion (from previously submitted Draft of EUR 2.5 billion over the period of 2022-2031). In addition, the total number of installed smart meters has exceeded 900 thousand.

In Customers & Solutions, we continue to expand the EV charging network in the Baltics and have now installed a total of 655 EV charging points (+279 since 31 December 2023).

Sustainability

Our Green Share of Generation amounted to 84.8% (-7.7 pp YoY) as a result of proportionally higher electricity generation in CCGT (Reserve Capacities).

We reduced our GHG emissions by 41.9% in Scope 2, while our Scope 1 and Scope 3 emissions increased by 19.2% and 5.9% respectively compared to 6M 2023. Total emissions amounted to 3.04 million t CO2-eq (+14.4% YoY). This rise was expected and is mainly attributable to a 237.6% increase in out of scope (biogenic) emissions from the Vilnius CHP biomass unit's operations (the unit has reached full COD in May 2024).

The carbon intensity of our Scope 1 and 2 GHG emissions decreased to 256 g CO2-eq/kWh (-28.6% YoY), due to lower Scope 2 emissions and higher electricity generation from renewables.

No fatal accidents were recorded. Our employee TRIR was 1.00, contractor TRIR - 0.21, both well below the targeted threshold. Our eNPS remained high at 66.5.

Shareholder returns and 2024 outlook

In line with our Dividend Policy, for 6M 2024 we propose to distribute a dividend of EUR 0.663 per share, corresponding to EUR 48.0 million, which is subject to the decision of our EGM to be held on 11 September 2024.

Following our strong performance, we increase our 2024 Adjusted EBITDA guidance to EUR 450-480 million (from EUR 440-470 million). Our Investments guidance remains in the range of EUR 850-1,000 million.

Key financial indicators (APM1)

EUR, millions 6M 2024 6M 2023 Change
Adjusted EBITDA289.7 253.5 14.3%
Green Capacities 134.5 109.1 23.3%
Networks 115.7 88.7 30.4%
Reserve Capacities 25.2 32.2 (21.7%)
Customers & Solutions 11.8 21.7 (45.6%)
Other activities and eliminations2 2.6 1.9 36.8%
Adjusted EBITDA Margin26.6% 18.3% 8.3 pp
EBITDA294.2 239.9 22.6%
EBITDA Margin26.9% 17.5% 9.4 pp
Adjusted Net Profit 164.6 150.1 9.7%
Net Profit168.4 155.8 8.1%
Net Profit Margin 15.4% 11.4% 4.0 pp
Investments 422.3 402.6 4.9%
Green Capacities 269.6 234.0 15.2%
Networks 135.8 161.9 (16.1%)
Reserve Capacities 0.5 1.3 (61.5%)
Customers & Solutions 7.8 2.1 271.4%
Other activities and eliminations2 8.6 3.3 160.6%
FFO225.4 161.7 39.4%
FCF? (105.0) 50.2 n/a
Adjusted ROE LTM 13.5% 14.2% (0.7 pp)
ROE LTM 15.0% 15.9% (0.9 pp)
Adjusted ROCE LTM 10.4% 11.3% (0.9 pp)
ROCE LTM 11.6% 13.0% (1.4 pp)
Basic earnings per share2.33 2.15 8.4%
30 Jun 2024 31 Dec 2023 Change
Net Debt1,411.0 1,317.5 7.1%
Net Working Capital113.7 175.2 (35.1%)
Net Debt/Adjusted EBITDA LTM, times2.71 2.72 (0.4%)
FFO LTM/Net Debt32.0% 29.4% 2.6 pp

1?All, except Net profit, are Alternative Performance Measures (APMs). Definitions and formulas of the financial indicators are available on our website.
2 Other activities and eliminations - includes consolidation adjustments, related-party transactions, and the financial results of the parent company.

Earnings call

In relation to the announcement of the 6M 2024 results, an earnings call will be held on Wednesday, 14 August 2024, at 1:00 pm Vilnius / 11:00 am London time.

To join the earnings call, please register at: https://edge.media-server.com/mmc/go/Ignitis6M2024results/

It will be also possible to join the earnings call by phone. To access the dial-in details please register here. After completing the registration, you will receive dial-in details on screen and via email. You will be able to dial in using the provided numbers and the unique pin or by selecting 'Call me' option and providing your phone details for the system to connect you in automatically as the earnings call starts.

All questions can be directed in advance to the Group's investor relations team, after registering for the earnings call or live, during the call.

Presentation slides will be available prior to the call:
https://ignitisgrupe.lt/en/reports-and-presentations

The interim report, including the fact sheet (in Excel), will be available for download at:
https://ignitisgrupe.lt/en/reports-and-presentations

For additional information, please contact:

Communications
Arturas Ketlerius
+370 620 76076
arturas.ketlerius@ignitis.lt

Investor Relations
Aine Riffel-Grinkeviciene
+370?643 14925
aine.riffel-grinkeviciene@ignitis.lt


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.